I found this topic in the news, which motivated me to explore it further and write this article. I want to give credit to the original source.
Diabetes is more than just high blood sugar. Over time, the disease harms blood vessels and nerves, which limits circulation, especially in the legs and feet. Poor blood flow can turn a small cut into a serious wound, often leading to ulcers, infections, and in severe cases, amputations. Traditional treatments for these complications have been invasive, expensive, and risky. However, a new breakthrough from researchers in Hong Kong offers fresh hope with a non-invasive approach.
Recently, scientists at the Chinese University of Hong Kong (CUHK) developed a new therapy that improves blood circulation in diabetic patients without surgery. According to the South China Morning Post (2024), the treatment uses cytokines proteins from the immune system to encourage the growth of new blood vessels. For millions of people living with diabetes around the world, this could lead to fewer amputations, quicker healing, and a better quality of life.
I think this development is particularly exciting because it blends modern biomedical science with the practicality patients need: a therapy that is effective, safe, and non-invasive. Let’s explore why this is so important.
WHY BLOOD FLOW MATTERS IN DIABETES
Diabetes damages the body’s blood vessels through a process called endothelial dysfunction. High glucose levels trigger inflammation, oxidative stress, and thickening of blood vessel walls. Over time, this reduces circulation, especially in small vessels that supply the feet and toes.
The consequences are severe:
• Diabetic foot ulcers develop in around 15 to 25% of patients during their lifetime.
• Infections are harder to treat due to poor blood supply.
• Amputations remain tragically common. The International Diabetes Federation (2023) reported that every 30 seconds, somewhere in the world, a leg is lost to diabetes.
Let’s explore why current treatments have not been effective. Traditional approaches, such as angioplasty, bypass surgery, or even amputations, are invasive. They carry risks of infection and long recovery times, making them often unsuitable for elderly or fragile patients. That’s why CUHK’s non-invasive alternative is so important.
THE HONG KONG BREAKTHROUGH: CYTOKINE THERAPY
The CUHK research team tested two cytokines, interleukin-4 (IL-4) and interleukin-13 (IL-13). These proteins help control inflammation and tissue repair. When injected into diabetic mice with poor circulation, they caused the growth of new capillaries, restoring blood flow to the affected tissues.
The most exciting part is that this method does not require opening arteries or inserting stents. Instead, the therapy acts like a “biological switch” that tells the body to heal itself by creating new blood vessels.
Let’s explore what makes this so friendly for patients. The scientists see this being delivered as an injection, similar to how insulin or vaccines are given. This makes it a non-invasive treatment that can be done in a clinic. If it works well in humans, it could change diabetic wound care around the world.
COMPARING INVASIVE VS. NON-INVASIVE APPROACHES
To appreciate the value of this breakthrough, consider the difference:
Invasive treatments:
• Angioplasty: threading a catheter into arteries to insert a balloon or stent.
• Bypass surgery: using grafts to reroute blood flow.
• Amputation: removing tissue when damage cannot be repaired.
These methods can save lives but come with surgical risks, high costs, and emotional stress.
Non-invasive treatments (like CUHK’s cytokine therapy):
• No major surgery.
• Less risk of infection.
• Can be given multiple times in a clinic.
• Supports the body’s natural healing instead of replacing damaged vessels.
In my opinion, this is one of the most patient-friendly advances we’ve seen in recent years. It avoids the risks of surgery while offering the chance to save limbs.
PHARMACISTS ’s PERSPECTIVE: WHAT THIS MEANS FOR PATIENTS
Now, let’s explore the implications of this innovation from a pharmacist’s view.
I see three key points:
1 Accessibility: If cytokine therapy becomes available by injection, it could fit into outpatient care, similar to insulin or other biologics. This would reduce the need for expensive hospital procedures.
2. Complementary Role: This therapy isn’t a cure-all. Patients will still have to manage their blood sugar, cholesterol, and blood pressure. Medications such as statins, ACE inhibitors, and antiplatelets will still be important. However, cytokine injections could provide an additional layer of support for circulation.
3. Patient Education: Many patients are cautious about new treatments. I believe pharmacists will be essential in explaining that cytokines are natural immune proteins, not synthetic chemicals, and that the therapy helps promote the body’s own repair mechanisms.
EVIDENCE AND SCIENTIFIC BACKING
The CUHK study, still in preclinical stages, rests on strong evidence. Research in Nature Communications and other journals has shown that cytokines can control vascular remodeling and tissue repair. Similar biologic therapies are already effective for conditions like rheumatoid arthritis and asthma, showing that immune proteins can be safely used in medicine.
Additionally, the non-invasive nature of injections could make regulatory approval and patient acceptance easier than for surgical devices. Clinical trials in humans will be the next important step.
What Patients Can Do Now
While we wait for this therapy to become available in clinics, there are evidence-supported actions patients can take today to support their circulation:
• Control blood sugar: Keeping glucose levels in check reduces vascular damage.
• Stay active: Walking and exercising boost natural blood flow.
• Quit smoking: Tobacco greatly worsens circulation issues.
• Foot care: Inspecting feet daily and treating wounds promptly can prevent complications.
• Medication adherence: Taking blood pressure, cholesterol, and antiplatelet medications is vital for protecting blood vessels.
I believe pharmacists can effectively guide patients through these steps while also keeping them informed about new treatments like cytokine therapy.
LOOKING AHEAD: A SHIFT IN DIABETES CARE
The CUHK breakthrough could signify a change in diabetes care, moving from reactive, invasive procedures to proactive, regenerative treatments. Picture a future where, instead of amputations, patients receive a series of safe injections that restore circulation before wounds worsen. This isn’t just a dream. With clinical trials on the way, there is real hope. If proven effective in humans, cytokine therapy could become another significant innovation in diabetes management, alongside insulin.
FINAL THOUGHTS
Diabetes is unforgiving, but science is tirelessly seeking solutions. The new cytokine therapy developed by scientists in Hong Kong offers hope: a non-invasive, biologically smart way to restore blood flow and avoid amputations.
I find this approach exciting because it focuses on patients, is practical, and is based on strong science. It has the power to save limbs and reduce the burden of surgery, hospitalization, and the anxiety many patients face.
As research continues, both patients and healthcare providers should stay informed. The future of diabetes care may rely not on scalpels and stents, but on proteins that unlock the body’s natural ability to heal.
FAQs
1. Is this new diabetes treatment already available for patients?
No, the treatment is still under research and clinical trials. It has not yet been approved for general medical use.
2. Does it replace current diabetes medicines or insulin?
Not at this stage. Patients should continue their prescribed medications and treatment plans until new therapies are officially approved by regulatory bodies.
3. What makes this treatment different from current options?
Unlike traditional drugs that mainly target blood sugar levels, this approach aims to improve blood flow, which may help reduce long-term complications of diabetes.
4. Are there any risks involved?
Since the treatment is still under investigation, researchers are carefully studying its safety and effectiveness. More evidence is needed before conclusions can be made.
DISCLAIMER
This article is for educational purposes only. It does not provide medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before making changes to your diabetes management or treatment plan.
CALL-TO-ACTION
Interested in staying updated on the latest diabetes research and safer treatment options?
Subscribe to Pharmahealths for evidence-based health insights from a pharmacist’s perspective.
REFERENCES:
• South China Morning Post (2024). Hong Kong scientists developing new blood flow treatment to aid diabetes patients.
• International Diabetes Federation. IDF Diabetes Atlas, 2023.
• Nature Communications (2022). Role of IL-4 and IL-13 in vascular remodeling and angiogenesis. • American Diabetes Association. Standards of Medical Care in Diabetes, 2024.